cDNA sequencing of the 5' noncoding region (5' NCR) to determine hepatitis C genotypes in patients with chronic hepatitis C

Christopher B. O'Brien, Barbara S. Henzel, Larry Wolfe, Karen Gutekunst, Dilip Moonka

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Reports suggest that response to interferon-α therapy is influenced by both hepatitis C viral genotype and titer. Our aim was to determine if direct, automated, cycle sequencing of the PCR product from an HCV RNA detection assay could be used to reliably determine HCV genotype. In addition, the approach was used to determine the HCV genotype distribution in our patient population and to learn if there was a correlation between HCV genotype and RNA titer that could be used to predict response to treatment. In all 143 consecutive patients were tested for both HCV RNA titer and genotype. Automated, cycle sequencing of PCR product was highly effective and failed to yield a genotype in only 3 (2%) patients. The distribution of HCV genotypes was: la (40%), lb (39%), 2a (2%), 2b (6%), 3a (4%). There were significant differences in the median HCV RNA titers between genotypes 1, 2, and 3. High HCV RNA titers >4.4 x 106 copies/ml were only seen in genotype 1. However, the HCV RNA level should not be used as a surrogate marker of genotype because of a significant overlap of titers within the genotypes.

Original languageEnglish (US)
Pages (from-to)1087-1093
Number of pages7
JournalDigestive Diseases and Sciences
Volume42
Issue number5
DOIs
StatePublished - Jun 19 1997
Externally publishedYes

Keywords

  • Flaviviridae
  • genotype
  • hepatitis C
  • interferon- α
  • polymerase chain reaction

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'cDNA sequencing of the 5' noncoding region (5' NCR) to determine hepatitis C genotypes in patients with chronic hepatitis C'. Together they form a unique fingerprint.

  • Cite this